We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CSL:NYSECarlisle Companies Incorporated Analysis

Data as of 2026-08-25 - not real-time

$361.76

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

The moving-average structure behind Carlisle Companies Incorporated is bullish at $361.76, with short-term averages leading the long-term ones. Over a rolling month the price has gained 6.9%. With RSI at 49.1 the momentum picture is neutral, alongside a bearish MACD signal. Watch $320.23 as support and $393.30 as the nearer resistance level.
On valuation the read is fair — earnings multiple of 20.5 versus a 29.7 sector average, below the peer group. Analyst price targets sit 13.9% above the current price. Revenue is growing at 8.3% on a 14.2% profit margin. The 1.38% dividend yield looks covered by current payout levels.
Risk comes out at 6 of a possible 10, a elevated reading. With 30-day volatility of 46.2%, a beta of 1.17 and a maximum drawdown of 25.4%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: buy, at a conviction of 5 out of 10.

Top Market Events

Carlisle CSL stock is upgraded to Buy after strong Q2 2026 results and ~19% undervaluation; see outlook,...Carlisle delivered a record quarter with EPS and revenue both topping expectations by double digits, while raising...Building envelope solutions provider Carlisle Companies NYSE:CSL announced better-than-expected revenue in Q2 CY2026,...

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 5/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 349.96
  • MACD momentum is negative

Medium Term

1–3 years
Positive
Model confidence: 5/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 20.5 versus sector average of 29.7
  • Trading above the 200-day average of 349.96

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • P/E of 20.5 versus sector average of 29.7
  • Analyst targets imply +13.9% versus the current price
  • Return on equity of 39.2%

Key Metrics & Analysis

Financial Health

Revenue Growth8.30%
Profit Margin14.21%
P/E Ratio20.5
ROE39.18%
ROA10.81%
Debt/Equity178.70
P/B Ratio8.9
Op. Cash Flow$1.0B
Free Cash Flow$669.7M
Industry P/E29.7

Technical Analysis

TrendBullish
RSI49.1
Support$320.23
Resistance$393.30
MA 20$370.71
MA 50$358.50
MA 200$349.96
MACDBearish
VolumeDecreasing
Fear & Greed Index93.23

Valuation

Fair Value$248.53
Target Price$412.14
Upside/Downside13.93%
GradeFair
TypeBlend
Dividend Yield1.38%

Risk Assessment

Beta1.17
Volatility46.22%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.